Kura Oncology, which is developing treatments of various cancers based on molecular biomarkers, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.
The La Jolla, CA-based company, which was founded in 2014, plans to list on the Nasdaq under the symbol KURA. Citi and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
